Longevity science projects funded by VitaDAO

VitaDAO primarily funds translational R&D. We are particularly interested in ‘moonshots’ – potential revolutionary contributions to science. On occasion we will also fund more ‘basic’ research and other projects in the interests of the LongBio community.

Explore our portfolio of funded projects, or follow the link below to submit your own project for funding.

Click here to explore the VitaDAO Project Funding FAQ.

$4.2M+

Funding Deployed

22

Research Projects Funded

200+

Projects Evaluated

$6M+

Liquid Funds

Featured Projects
IP-NFTs & Research Projects

Matrix Bio - Long-lived Species Inspired Longevity Biotech

IP-NFT

VitaDAO and the Gorbunova Lab are launching Matrix Bio, a cutting-edge research venture leveraging the anti-cancer and pro-longevity effects of high molecular weight hyaluronic acid from naked mole rats to humans.

$ 300,000
allocated
View Project

Discovering Novel Autophagy Activators - Korolchuk Lab

IP-NFT

Autophagy - the mechanism to recycle cellular components - becomes dysregulated with age and is associated with numerous diseases. The Korolchuk lab, based at Newcastle University, will screen a compound library to identify novel autophagy-activating compounds with the aim of restoring autophagy function to aged cells.

$ 285,000
allocated
View Project

The Longevity Molecule - Scheibye-Knudsen Lab

IP-NFT

What if therapeutics to slow down the aging process and prevent age-related disease already existed? The Scheibye-Knudsen Lab will use advanced machine learning to crunch the data from 1.04 billion prescriptions to understand the impact of drugs on human lifespan.

$ 250,000
allocated
View Project

ApoptoSENS - Senolytic CAR-NK Cells

IP-NFT

SENS Research Foundation researcher Dr. Amit Sharma has identified senescence-specific cell surface biomarkers, leading to the development of Chimeric Antigen Receptor Natural Killer (CAR-NK) cells that can eliminate senescent cells in vivo. This innovative approach holds promise for combating age-related diseases and extending lifespan.

$ 253,000
allocated
View Project

Novel Mitophagy Activators for Alzheimer’s Disease - Fang Lab

IP-NFT

Mitophagy - the mechanism to recycle mitochondria - becomes dysregulated with age and is thought to be a driver of Alzheimer’s and other age-related diseases. The Fang lab aims to use a combination of artificial intelligence and a wet-lab validation platform to identify new mitophagy-activating drug candidates.

$ 300,000
allocated
View Project

Reversing Periodontal Disease using Geroscience - An Lab

IP-NFT

The greatest underlying risk factor for periodontitis is age, and its association with other age-related diseases. Jonathan An’s lab proposes to test a series of compounds targeting inflammation in a mouse model of age-related periodontitis, with the goal of finding a geroscience-based treatment for this neglected disease that has a severe impact on human healthspan.

$ 330,000
allocated
View Project

Probing DNA Quadruplexes in Age Related Proteostasis

IP-NFT

This project explores the role of DNA Helicases (WRN and BLM) and DNA quadruplexes (G4) structures in healthy and unhealthy aging and probing both the wanted and unwanted G4 structures and their impact on proteostasis maintenance, which may create the opportunity for novel drug targets.

$ 50,000
allocated
View Project

ARTAN Bio - Mutation-Specific Codon Suppression for Aging and Longevity

IP-NFT

ARTAN is a biotechnology company developing first-in-class interventions to tackle the most frequent nonsense mutations implicated in a wide range of age-related diseases and cancers. These nonsense mutations induce premature stops of protein translation when occurring in coding regions.

$ 91,300
allocated
View Project
Equity Deals

Humanity - Proprietary Aging Score App

Equity

Humanity is a quantified-self app that connects wearables and activity apps to monitor digital biomarkers. The app generates a proprietary aging score, helping users understand activities that slow down or reverse their aging rate. The company uses behavior modification tools and develops biomarkers to guide users toward better healthspan interventions.

$ 50,000
allocated
View Project

BE Therapeutics - Brain Tissue Replacement

Equity

The neocortex, the part that underlies our highest cognitive functions and self-identity, can be replaced by progressively replacing tissue areas over time without significant disruption in function or self-identity. This offers the possibility of age reversal for the neocortex through progressive tissue replacement.

$ 100,000
allocated
View Project

ExcepGen Inc - RNA therapeutics for longevity

Equity

ExcepGen uses its RNAx platform to develop advanced vaccines that address viral infections linked to premature aging and shortened lifespan. The platform improves RNA cargo's effectiveness, promoting significant protein production for enhanced protection.

$ 100,000
allocated
View Project

Cyclarity - Novel Cyclodextrin Molecules for Multiple Aging-related Diseases

Equity

Cyclarity Therapeutics is an early stage biotechnology company developing computationally designed novel cyclodextrin drug molecules for the extraction of toxic biomolecules that accumulate with age and are implicated in a variety of age-related conditions.

$ 50,000
allocated
View Project

GERO - Physics and AI Technology Platform for Age-Related Diseases

Equity

GERO uses physics and AI to develop a proprietary technology platform to understand the aging process and create a pipeline of drug candidates and therapies targeting multiple age-related chronic diseases. Their ultimate aim is to dramatically slow down aging.

$ 100,000
allocated
View Project

HDAX Therapeutics - Histone Deacetylase Targeting Drug Discovery

Equity

HDAX is a preclinical-stage drug discovery company targeting a class of proteins implicated in neuropathies and inflammation with novel small molecules.

$ 50,000
allocated
View Project

Remedium Bio - Gene Therapy for Regenerative Medicine

Equity

Remedium Bio is a regenerative medicine biotechnology company, that has developed the only dose-adjustable gene therapy platform technology Prometheus™ and is currently advancing multiple assets with uncorrelated risk to Investigational New Drug (IND) approval.

$50,000
allocated
View Project

Oisín Biotechnologies - Pioneering Genetic Medicines for Sarcopenia

Equity

Oisín Biotechnologies is a multi-asset longevity biotech company pioneering genetic medicines to combat sarcopenia and other age-related diseases to promote healthier, longer lives.

$50,000
allocated
View Project

Turn Biotechnologies - mRNA Therapeutics with Lipid Nanoparticle Delivery

Equity

Turn Bio develops mRNA medicines that induce the body to heal itself by instructing specific cells to fight disease or repair damaged tissue. They are reprogramming the epigenome – a network of chemical compounds and proteins controlling cell functions to restore capabilities that are lost with age.

$ 1,000,000
allocated
View Project

ImmuneAge Bio - Rejuvenation of Aged HSCs

Equity

ImmuneAGE Bio is the first drug discovery platform company focused on immune system rejuvenation. ImmuneAGE rejuvenates hematopoietic stem cells (HSCs) from the bone marrow based on a geroscience screening platform enabled by a new ‘StemSupply’ method achieving >1000x expansion of HSCs.

$ 50,000
allocated
View Project

Rubedo.Life - Prodrug Discovery Platform

Equity

Rubedo is building a platform for longevity medicines using “smart drugs” (prodrugs) that have the capacity to selectively be activated in target cells predicted to be pathogenic and the cause of age-related diseases.

$ 350,000
allocated
View Project

Etheros - Fullerene Chemistry for Longevity

Equity

Etheros is developing a new class of small molecule drugs based on fullerene chemistry. The lead compound has shown to extend mouse lifespan, improve cognition in elderly mice, and has been neuroprotective in various animal studies. The compounds mimic enzymes that protect cells from oxidative and inflammatory injury. The current raise will help Etheros improve its IP portfolio

$ 50,000
allocated
View Project

Repair Biotechnologies - First-in-class Cell Therapy for Atherosclerosis

Equity

Repair Biotechnologies is a preclinical-stage biotech company developing a first-in-class universal cell therapy for atherosclerosis. It aims to reduce the risk of cardiovascular events, such as heart attack and stroke.

$ 50,000
allocated
View Project

Mantis Photonics - Hyperspectral Imaging for Degenerative Disease

Equity

Mantis Photonics AB is developing a hyperspectral camera for retinal imaging for the early screening of Alzheimer's Disease via the detection of the Amyloid beta peptide. The retina displays similarities to the brain and spinal cord in terms of anatomy, functionality and response to insult, hence, the eye providing a unique window to the central nervous system.

€ 30,000
allocated
View Project

Zoe Biosciences - PAI-1 Antibody Therapeutics

Equity

An early-stage therapeutic biotech with two programs - each centered on targets that are well-validated both for longevity and aging-related diseases.

€ 100,000
allocated
View Project

Longevity Hackers Film Participation

Equity

A groundbreaking documentary examining the latest research and scientific breakthroughs in the field of longevity and healthy life extension. Featuring wide-ranging interviews from the researchers leading the charge to longevity critics, the film aims to educate and raise awareness, whilst providing a balanced analysis of this exciting and pioneering space.

$ 100,000
allocated
View Project
Initiatives

The Longevity Prize

Initiative

The Longevity Prize is a series of prizes to award and accelerate progress in longevity and rejuvenation research. It was initiated by VitaDAO and funded through donations through our gitcoin quadratic donation round and partnered with Foresight Institute, Methuselah Foundation and Lifespan.

$ 24,000
allocated
View Project

The VitaDAO Longevity Fellowship

Initiative

The VitaDAO Longevity Fellowship is aimed at distributing need-based micro grants to help students and early career stage individuals with interest in longevity get more deeply involved in longevity. This is aimed at activities ranging from short term research to attending a conference, or joining a program such as the Longevity Biotech Fellowship.

$ 20,000
allocated
View Project

The Longevity Decentralized Review (TLDR)

Initiative

The Longevity Decentralized Review (TLDR) is an on-demand service that provides peer reviews of scientific manuscripts and compensates reviewers for their work. It is funded from fees of those who submit their research to be reviewed, as well as donations. The focus of the content is longevity research posted to preprint servers such as Biorxiv, Medrxiv, and Arxiv.

20,000 VITA
allocated
View Project

The Longevist - Overlay Longevity Research Journal

Initiative

An overlay journal to curate the most impactful longevity research every quarter, as voted by a mix of industry & academic experts in the longevity space.

$ 50,000
allocated
View Project

Longevity Quadratic Funding

Initiative

Committed to magnifying public good project impact, VitaDAO, among other donors, pledges substantial matching funds for curated longevity projects, leveraging crypto communities for groundbreaking research.

$ 104,000
allocated
View Project

Zuzalu

Initiative

Initiated by Vitalik Buterin, Zuzalu is a pioneering experiment in social innovation and community-driven progress. With VitaDAO's backing, Zuzalu is exploring the multiple facets of longevity science; from biotech innovation to rethinking traditional frameworks that govern medical research. Zuzalu’s first pop-up city was co-organised by VitaDAO and attended by some of the world’s most accomplished builders, futurists, and social visionaries.

allocated
View Project
Initiatives

The Longevity Prize

Initiative

The Longevity Prize is a series of prizes to award and accelerate progress in longevity and rejuvenation research. It was initiated by VitaDAO and funded through donations through our gitcoin quadratic donation round and partnered with Foresight Institute, Methuselah Foundation and Lifespan.

$ 24,000
raised
View Project

The VitaDAO Longevity Fellowship

Initiative

The VitaDAO Longevity Fellowship is aimed at distributing need-based micro grants to help students and early career stage individuals with interest in longevity get more deeply involved in longevity. This is aimed at activities ranging from short term research to attending a conference, or joining a program such as the Longevity Biotech Fellowship.

$ 20,000
raised
View Project

The Longevity Decentralized Review (TLDR)

Initiative

The Longevity Decentralized Review (TLDR) is an on-demand service that provides peer reviews of scientific manuscripts and compensates reviewers for their work. It is funded from fees of those who submit their research to be reviewed, as well as donations. The focus of the content is longevity research posted to preprint servers such as Biorxiv, Medrxiv, and Arxiv.

20,000 VITA
raised
View Project

The Longevist - Overlay Longevity Research Journal

Initiative

An overlay journal to curate the most impactful longevity research every quarter, as voted by a mix of industry & academic experts in the longevity space.

$ 50,000
raised
View Project

Are you working on the next longevity science breakthrough?

Click here to explore the VitaDAO Project Funding FAQ.

Frequently Asked Questions

Who can apply?
What types of projects do you fund?
What is the application structure?
Who owns IP from funded projects?
What project stages do you fund?